+91-8668442535
Home / Biotechnology / Global Hig

Global High Throughput Process Development Market By Product (Consumables and Reagents and Instruments), By Process (Upstream and Downstream), By Molecule Type (Monoclonal Antibodies, Vaccines, Recombinant Insulin, Human Growth Hormones and Others) - Growth, Future Prospects & Competitive Analysis, 2017 - 2025

For the purpose of this study, the various products studied include consumables, reagents, and instruments. The processes are classified as upstream and downstream.

Based on molecule type, this market is further segmented as monoclonal antibodies, vaccines, recombinant insulin, human growth hormones, and others. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

  • The geographic segmentation of the global high-throughput process development market is performed for the regions of North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.

Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global high-throughput process development market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global high throughput process development market. The major players in the high-throughput process development market are Agilent Technologies, Inc., Axxam S.P.A., Aurora Biomed, Bio-Rad Laboratories, Inc., Danaher Corporation, Hamilton Company, Merck Millipore Corporation, Perkin Elmer, Inc., Tecan Group Ltd., and Thermo Fisher Scientific, Inc.

Based on molecule type, the global high-throughput process development market is categorized into

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Insulin
  • Human Growth Hormone
  • Others

High-throughput process development is of prime importance, as there is a tantamount requirement for a robust, reproducible manufacturing process in the life science industries, as it is a critical pathway for the development of novel therapies. In order to meet regulatory requirements and technical challenges, a very good understanding of the critical processes and multiparameter involved in high-throughput process development is mandatory. In 2016, the monoclonal antibodies segment dominated the market mainly due to factors such as the rising adoption of targeted immunotherapy, the fact that they are a highly reproducible, scalable, and unlimited production source, and the fact that hybridomas serve as an immortal source for the production of monoclonal antibodies. The limitations of monoclonal antibodies are that the system is well developed for only mouse and rat models and not for other animals, and the USFDA stipulates that monoclonal antibodies intended for human use should be totally free from pathogens, including viruses. The vaccines segment is anticipated to register faster growth throughout the forecast period of 2017–2025, primarily due to the rising incidence of contagious diseases spread by vectors such as parasites, bacteria, and viruses and because vaccines are helpful in preventing the greater cost incurred during the treatment of infectious disease.

Based on process types, the global high-throughput process development market is categorized into:

  • Upstream
  • Downstream

In the current regulatory scenario, it often takes around a decade and a huge amount of money to promote a drug candidate from the development process to the shelves. There is a strong impetus for pursuing methodologies that can shorten this gap in process development and manufacturing. In 2016, the upstream segment held the largest market share, chiefly due to factors such as technological advancement in the production and development of biological drugs, a strong impetus from novel biotherapeutic clinical trials, optimization of growth kinetics for enhanced product development, and improvement in the inoculum by genetic engineering.

Downstream will be the fastest-growing segment throughout the forecast period of 2017–2025. Factors supporting the growth of this segment include technological advancement in the separation of biomass from the fermented broth by centrifugation and ultracentrifugation techniques and stringent regulatory guidelines stipulated by the USFDA, making it extremely important for the effective purification of active metabolites as there have been several incidents reported regarding biological drug-related serious adverse events.

Based on product types, the global high-throughput process development market is categorized into:

  • Consumables and Reagents
  • Instruments

The high-throughput process development market is driven by factors such as the rising prevalence of chronic diseases, an aging population, and the burgeoning requirement for the launch of novel drugs to counteract the multiple drug resistance of bacterial infections. In addition, an increasing number of diagnostic centers and growing physician awareness regarding disease etiology will propel market penetration for high-throughput screening. In 2016, the instruments segment held the largest market share, chiefly due to factors such as technological advancement in automation techniques and their huge application in biopharmaceuticals, contract research organizations, research institutes, etc.

Consumables and reagents will be the fastest-growing segment throughout the forecast period of 2017–2025, primarily due to factors such as the rising prevalence of chronic diseases, steadily increasing diagnostic centers, and public-private partnerships to combat life-threatening diseases by setting up research and development centers. The major players in the high-throughput screening market are Agilent Technologies, Inc., Axxam S.P.A., Aurora Biomed, Bio-Rad Laboratories, Inc., Danaher Corporation, Hamilton Company, Merck Millipore Corporation, Perkin Elmer, Inc., Tecan Group Ltd., and Thermo Fisher Scientific, Inc.

For the purpose of this study, the global high-throughput process development market is categorized into the following regional and country-specific markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of the Middle East and Africa

In the base year 2016, North America was observed to be the largest market for high-throughput process development. The dominance of North America is mainly attributed to the presence of major giants in the biotechnology and pharmaceutical industries, which focus on the novel drug discovery of biological drug candidates and the existence of advanced healthcare and research facilities. The market growth in Europe is mainly attributed to the increasing number of patients suffering from chronic diseases. This factor boosts demand for lowering the manufacturing cost of biological drugs and reducing product development timelines. Asia Pacific was observed as the fastest-growing regional segment throughout the forecast period of 2017–2025. The presence of a large patient pool that can be enrolled to study the safety and efficacy studies for biological drug candidates during clinical trials, as well as increased research and development spending by governmental organizations, are expected to propel market growth in Asia-Pacific. Moreover, factors such as developing healthcare infrastructure and public-private partnerships between major biopharmaceutical players and academic research institutes are going to fuel the rapid growth of the high-throughput process development market in Latin America, the Middle East, and Africa in the near future.

Frequently Asked Questions:

The market for High Throughput Process Development is expected to reach US$ 24,600.7 Mn in 2025.

The High Throughput Process Development market is expected to see significant CAGR growth over the coming years,at 9.55%

The report is forecasted from 2017-2025

The base year of this report is 2016.

Agilent Technologies, Inc.,Axxam S.P.A.,Aurora Biomed,Bio-Rad Laboratories, Inc.,Danaher Corporation are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Oct 2017
Category:  Biotechnology
Report ID:   58745
Report Format:   PDF
Pages:   120
Rating:    4.7 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support